{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-019133","form_type":"8-K","ticker":"TNGX","cik":"0001819133","company_name":"Tango Therapeutics, Inc.","filed_at":"2023-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.828326+00:00","generated_at":"2026-06-15T09:47:08.032835+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Tango Therapeutics Q1 net loss $0.32/sh; cash $334M funds pipeline into 2026","bullets":["Q1 net loss $28.0M ($0.32 per share) vs $25.2M ($0.29) in prior year; revenue flat at $5.8M.","Cash and equivalents $333.6M; expects to fund operations into 2026.","TNG908 shows proof-of-mechanism with selective PRMT5 inhibition in MTAP-deleted tumors; no DLTs or grade >2 AEs.","FDA cleared IND for TNG260 (CoREST inhibitor) and granted Fast Track designation for STK11-mutant NSCLC; phase 1/2 to start 2H 2023.","Appointed Adam Crystal, M.D., Ph.D., as President of R&D in February 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-019133","json":"https://secwatch.observer/filing/0000950170-23-019133.json","markdown":"https://secwatch.observer/filing/0000950170-23-019133.md","text":"https://secwatch.observer/filing/0000950170-23-019133.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819133/000095017023019133/0000950170-23-019133-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819133/000095017023019133/tngx-20220810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T09:47:08.032835+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5e2300c93a2f38ec5a0059aa83275d75b196d533","claim":"Tango Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2023.","evidence_excerpt":"Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the first quarter ended March 31, 2023, and provided business highlights.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819133/000095017023019133/0000950170-23-019133-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}